🟢 Capricor Therapeutics is trading 23.8% up in pre-market after HOPE-3 data showed slower upper-limb decline

Capricor Therapeutics is trading at $10.61, up +23.80%, after reports of HOPE-3 extension findings showing slower upper-limb and elbow-function decline among patients who switched from placebo to deramiocel.

• The findings were reported during the World Muscle Society Congress.
• The company had previously announced its Congress presentations, including 24-month HOPE-3 and extension outcomes; the scheduled event itself was not new news.